Abstract
A male infant with clinical features of Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy is reported. He manifested severe heart failure and failure to thrive. Administration of propranolol and cibenzoline improved ventricular outflow tract obstruction, leading to catch-up growth. Genetic analysis of the patient revealed a novel missense mutation in the PTPN11 gene. Conclusion:This is the first description of a patient with a Gln510Glu mutation in the protein-tyrosine phosphatase, non-receptor type 11 gene. This specific mutation may be associated with a rapidly progressive hypertrophic cardiomyopathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BNP :
-
B-type natriuretic peptide
- HCM :
-
hypertrophic cardiomyopathy
- LVOTO :
-
left ventricular outflow tract obstruction
- PTP :
-
protein tyrosine phosphatase
References
Bertola DR, Kim CA, Sugayama SM, Albano LM, Wagenfuhr J, Moyses RL, Gonzalez CH (2000) Cardiac findings in 31 patients with Noonan’s syndrome. Arq Bras Cardiol 75: 409–412
Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W (1993) Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 22: 1189–1192
Fragale A, Tartaglia M, Wu J, Gelb BD (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged Gab1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23: 267–277
Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, Ochi T, Hiwada K (1997) Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 96: 1520–1524
Hirsch HD, Gelband H, Garcia O, Gottlieb S, Tamer DM (1975) Rapidly progressive obstructive cardiomyopathy in infants with Noonan’s syndrome. Report of two cases. Circulation 52: 1161–1165
Judith E (1987) Noonan syndrome. J Med Genet 24: 9–13
Kalidas K, Shaw AC, Crosby AH, Newbury-Ecob R, Greenhalgh L, Temple IK, Law C, Patel A, Patton MA, Jeffery S (2005) Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11. J Hum Genet 50: 21–25
Klinghoffer AR, Kazlauskas A (1995) Identification of a putative Syp substrate, the PDGFß receptor. J Biol Chem 270: 22208–22217
Kosaki K, Suzuki T, Muroya K, Hasegawa T, Sato S, Matsuo N, Kosaki R, Nagai T, Hasegawa Y, Ogata T (2002) PTPN11 mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab 87: 3529–3533
Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B (1999) Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 135: 703–706
Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai K, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K, Hirano T, Kawase I, Hirota H (2003) Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res 93: 221–2219
Neel BG, Gu H, Pao L (2003) The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28: 284–293
Noonan J, O’Connor W (1996) Noonan syndrome: a clinical description emphasizing the cardiac findings. Acta Paediatr Jpn 38: 76–83
Pawson T, Scott DJ (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075–2080
Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi C, Fazio VM, Di Ciommo V, Marino B, Pizzuti A, Dallapiccola B (2003) Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet 40: 704–708
Schaeper U, Gehring HN, Fuchs PK, Sachs M, Kempkes B, Birchmeier W (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 149: 1419–1432
Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP (1997) A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart 77: 229–233
Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29: 465–468
Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD (2002) PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70: 1555–1563
Yoshida R, Hasegawa T, Hasegawa Y, Nagai T, Kinoshita E, Tanaka Y, Kanegane H, Ohyama K, Onishi T, Hanew K, Okuyama T, Horikawa R, Tanaka T, Ogata T (2004) Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab 89: 3359–3364
Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A (2004) Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144: 368–374
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takahashi, K., Kogaki, S., Kurotobi, S. et al. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr 164, 497–500 (2005). https://doi.org/10.1007/s00431-005-1679-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-005-1679-y